Ajai Chari, MD

Articles by Ajai Chari, MD

Patient Case 2: Managing Heavily Pre-Treated MM With Talquetamab

ByAjai Chari, MD,Krina K. Patel, MD, MSc,Alfred Garfall, MD,Sham Mailankody, MD

January 12th 2023

Switching focus to GPRC5-targeted bispecific antibody therapy, expert hematologist-oncologists review a patient case of relapsed/refractory MM managed with talquetamab.

BCMA-Targeting Bispecific Antibodies in RRMM: Managing ICANS and Infections

ByAjai Chari, MD,Krina K. Patel, MD, MSc,Alfred Garfall, MD,Sham Mailankody, MD

January 12th 2023

Closing out their module on BCMA-targeted therapy in relapsed/refractory MM, panelists highlight the optimal management of ICANS and infections.

BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS

ByAjai Chari, MD,Krina K. Patel, MD, MSc,Alfred Garfall, MD,Sham Mailankody, MD

January 5th 2023

Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.

Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD, MSc,Alfred Garfall, MD,Sham Mailankody, MD

January 5th 2023

Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.

Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD, MSc,Alfred Garfall, MD,Sham Mailankody, MD

December 29th 2022

A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab

ByAjai Chari, MD,Krina K. Patel, MD, MSc,Alfred Garfall, MD,Sham Mailankody, MD

December 29th 2022

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

Ajai Chari, MD, Talks Diversity in Multiple Myeloma Research

ByAjai Chari, MD

July 13th 2022

“What is more gratifying than people who are alive in complete remission for years?...The therapeutics are so effective and the symptoms of myeloma can be so rapidly reversed. It’s really gratifying.”

Ajai Chari, MD

Articles by Ajai Chari, MD

Patient Case 2: Managing Heavily Pre-Treated MM With Talquetamab

BCMA-Targeting Bispecific Antibodies in RRMM: Managing ICANS and Infections

BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS

Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab

Ajai Chari, MD, Talks Diversity in Multiple Myeloma Research

Trending on CancerNetwork

TOP Trial: Chemo-Osimertinib in TP53-Mutant EGFR-Mutated NSCLC

FLAURA2: Osimertinib Plus Chemo in EGFR-Mutant NSCLC

Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance

Sequencing ADCs and Managing Ocular Toxicities in Breast Cancer Populations

How Are CELMoDs Reshaping Treatment in Multiple Myeloma?